By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Intarcia


Drug Discovery

Company News
Intarcia Announces New Top-Line Phase III Results For Investigational Therapy ITCA 650 In Type 2 Diabetes 8/19/2015 8:14:26 AM
Intarcia Diabetes Implant Beats Merck & Co. (MRK)'s $6 Billion Drug in Head-to-Head Study 8/19/2015 6:38:22 AM
Intarcia Announces Presentations At American Diabetes Association Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 -- A GLP-1 RA For Type 2 Diabetes 6/8/2015 10:06:37 AM
Intarcia 's Kurt Graves Named An EY Entrepreneur Of The Year 2015 6/8/2015 7:22:25 AM
Intarcia To Announce Key ITCA 650 Phase 3 Findings And Other Data Presentations At Upcoming 75th Scientific Sessions Of The American Diabetes Association In Boston 6/3/2015 11:15:10 AM
Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 6/2/2015 1:58:07 PM
Intarcia Names Emad Rizk, MD, To Board Of Directors 5/19/2015 11:01:12 AM
Intarcia Named To "CNBC Disruptor 50" List: One Of Only Two Biopharma Companies Named 5/18/2015 10:53:00 AM
Intarcia Appoints James P. Brady Vice President, Human Resources 5/4/2015 9:24:42 AM
Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead Itca 650 Launch In U.S. 5/4/2015 9:23:50 AM